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Liver ﬁbrosis is the ﬁnal common pathway of chronic liver diseases irrespective of etiology.
However, etiology deeply impacts progression and characteristics of liver ﬁbrogenesis. IL-
13 is the dominant pro-ﬁbrotic cytokine in Schistosomiasis associated liver ﬁbrogenesis.
In vitro, IL-13 directly induces expression of ﬁbrosis-associated genes, e.g., collagens or
connective tissue growth factor, in hepatic stellate cells. Recently, potential effects of IL-13
in non-Schistosomiasis associated liver ﬁbrosis have been uncovered. This review sum-
marizes the potential roles of IL-13 in chronic liver disease of different etiologies, and the
downstream events mediating IL-13 signaling in liver ﬁbrogenesis.
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INTRODUCTION
Fibrosis is a leading cause of morbidity and mortality worldwide.
In theUSA,45%of all deaths can be attributed to ﬁbrotic disorders
(Wynn, 2004). In the liver, ﬁbrosis and its end stage, cirrhosis, is the
ﬁnal common pathway of chronic liver diseases irrespective of eti-
ology (Iredale, 2007). Liver cirrhosis represents not only increased
scarring and ﬁbrosis, but also distortion of the liver architecture in
association with nodule formation and altered blood ﬂow (Fried-
man, 2008). Patients with liver cirrhosis are facing tremendous
risks of hepatic failure and hepatocellular carcinoma (Friedman,
2008). So far, there is no gold-standard treatment for liver ﬁbrosis
and cirrhosis.
Advancement of liver ﬁbrosis is a dynamic process charac-
terized by accumulation exceeding degradation of extracellular
matrix (ECM). Over the last two decades, sinusoidal resident
hepatic stellate cells (HSC) have been commonly recognized as
the major source of ECM. In most chronic liver diseases, HSC
activation and transdifferentiation into myoﬁbroblasts (MFBs)
are key events in liver ﬁbrogenesis (Friedman, 2008). The initi-
ation phase of HSC activation is due to paracrine stimuli from
injured neighboring cells, including hepatocytes, Kupffer cells,
sinusoidal endothelial cells, platelets, and inﬁltrating inﬂamma-
tory cells. These damaged cells secret a number of cytokines to
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activate HSC. One important cytokine among them is transform-
ing growth factor (TGF)-β. Activated HSC perpetuate their own
activation by several autocrine loops, including the secretion of
TGF-β andupregulationof its receptors. Furthermore,overexpres-
sion of TGF-β promotes HSC survival in damaged liver (Bataller
and Brenner, 2005; Mann and Marra, 2010).
As the most important pro-ﬁbrotic mediator in liver ﬁbro-
sis (Gressner et al., 2002; Friedman, 2008), the role of TGF-β
has been intensively studied in a large amount of in vitro and
animal models. However, in patients with chronic liver diseases,
the effects of TGF-β in liver ﬁbrogenesis are etiology dependent
(Weng et al., 2009). For example, TGF-β and its downstream
signaling protein, phospho-Smad2, display high positive corre-
lation with ﬁbrosis degree in patients with chronic HBV infection,
alcoholic steatohepatitis (ASH), and non-alcoholic steatohepatitis
(NASH), but not in those with chronic HCV infection. In patients
infectedwith Schistosomamansoni orS. japonicum,TGF-βdemon-
strates negative correlation with ﬁbrosis stages (Weng et al., 2009;
Table 1).
Besides TGF-β, Interleukin (IL)-13 is recognized as another
critical pro-ﬁbrotic cytokine in various organs, including liver. It
has been identiﬁed as the dominant effector cytokine of Schistoso-
miasis associated liver ﬁbrogenesis (Wynn, 2003, 2004, 2008). Over
the last decade, the potential roles of IL-13 in non-Schistosomiasis
associated liver ﬁbrogenesis were reported (Weng et al., 2009; Jin
et al., 2011). In this review, we aim to provide up-to-date infor-
mation on the role of IL-13 and its downstream signaling in
ﬁbrogenesis, especially in the liver.
IL-13 IN LIVER FIBROSIS
SCHISTOSOMIASIS
IL-13 directly induces expression of collagen I and other critical
ﬁbrosis-associated genes, e.g., α-smooth muscle actin (SMA) and
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Table 1 | Correlation betweenTGF-β/p-Smad2 and IL-13 in liver fibrosis patients with different etiologies.
TGF-β/p-Smad2 IL-13
HBV High positive correlation (Stickel et al., 2001; Akpolat et al., 2005;
Weng et al., 2009)
Positive correlation (Weng et al., 2009)
HCV No correlation (Roulot et al., 1995;Weng et al., 2009) Positive correlation (Weng et al., 2009)
ASH High positive correlation (Weng et al., 2009) High positive correlation (Weng et al., 2009)
NASH High positive correlation (Weng et al., 2009) High positive correlation (Shimamura et al., 2008;Weng et al.,
2009)
Schistosomiasis Negative correlation (Alves Oliveira et al., 2006;Weng et al., 2009) High positive correlation (Booth et al., 2004;Weng et al., 2009)
Others Unknown Unknown
connective tissue growth factor (CTGF), in HSC, the major ECM
producing source during liver ﬁbrogenesis (Sugimoto et al., 2005;
Weng et al., 2009; Liu et al., 2011). So far,most studies involving the
role of IL-13 in liver ﬁbrogenesis are implicated in Schistosomia-
sis. S. mansoni or S. japonicum infection causes serious pathogenic
changes in human organs, including lung, intestine, and especially
liver (Wynn et al., 2004b). The worms inside human mesen-
teric veins lay numerous eggs that are ﬁnally carried to the liver
and deposited in portal veins. The eggs induce granulomas and
lead to liver ﬁbrosis (Wynn et al., 2004b). From acute to chronic
infection of Schistosoma, patients with Schistosomiasis undergo
T-cell polarization from Th1 cell to Th2 cell dominant (Wynn,
2003). Due to its predominant role in Th2 development, IL-4
is hypothesized as a potential crucial cytokine regulating schis-
tosoma associated liver ﬁbrosis. Interfering with IL-4 inﬂuences
liver ﬁbrogenesis in S. mansoni infected mouse models has been
reported in early studies (Cheever et al., 1994, 1999). Cheever and
colleagues showed that neutralizing IL-4 by antibody markedly
decreases hepatic collagen deposition. In addition, anti-IL-4 treat-
ment decreases mRNA expression of Th2 cytokines, e.g., IL-5 and
IL-13, and increases mRNA expression of Th1 cytokines, e.g.,
IFN-γ and IL-2, in the liver infected with S. mansoni (Cheever
et al., 1994). Later, the same group found that severe combined
immunodeﬁciency (SCID) mice formed smaller hepatic granulo-
mas and less ﬁbrosis compared to wild-type mice. The reduction
in egg-associated pathology in SCID mice correlates with marked
decreases in mRNA expression of IL-4, IL-5, IL-13, and IFN-γ in
the liver (Cheever et al., 1999). However, IL-4 knockout (KO) mice
infected with S. mansoni do not signiﬁcantly reduce granuloma
volume (Cheever et al., 1994; Metwali et al., 1996; Pearce et al.,
1996). Jankovic et al. compared schistosoma associated pathology
between IL-4 KO and IL-4 receptor KO mice. In contrast to IL-4
KO mice, IL-4 receptor KO mice developed only minimal hepatic
granulomas and ﬁbrosis despite the equivalent lymphocytic pro-
ﬁle in both models (Jankovic et al., 1999). These results suggest
that IL-4 receptor associated factors, but not IL-4, are critical for
regulating granuloma formation.
Subsequently three hallmark studies compared the role of IL-4
and IL-13 in granuloma formation and liver ﬁbrosis of S. man-
soni infected mice (Chiaramonte et al., 1999a,b; Fallon et al.,
2000). Chiaramonte et al. (1999b) conﬁrmed that IL-13 is the key
cytokine to regulate granuloma formation in S. mansoni infected
mice. They showed that IL-4 KO mice do not decrease collagen I
and III expression after S. mansoni infection (Chiaramonte et al.,
1999b; Fallon et al., 2000). In contrast to IL-4, a soluble IL-13
receptor α2-Fc-fusion protein (sIL-13Rα2-Fc), which successfully
neutralizes IL-13 in vitro and in vivo (Donaldson et al., 1998;
Chiaramonte et al., 1999b), markedly inhibits expression of colla-
gen I and III (Chiaramonte et al., 1999a). Using IL-4 KO, IL-13 KO
and IL-4/IL-13 double KO mice, Fallon et al. found that both IL-4
and IL-13 are required for granuloma formation in mice infected
with S. mansoni. IL-4 or IL-13 single knockout does not inﬂu-
ence granuloma volume in the liver after S. mansoni infection.
However, IL-4/IL-13 double KO mice demonstrated signiﬁcantly
reduced granuloma in the liver as compared to wild-type or IL-
4/IL-13 single knockout mice. IL-13 KO and IL-4/IL-13 double
KO mice markedly improved liver ﬁbrosis whereas IL-4 KO does
not change collagen deposition and liver ﬁbrosis after S. mansoni
infection (Fallon et al., 2000). These results clearly suggest that
IL-4 and IL-13 have distinct roles in S. mansoni infected mice and
that IL-13, but not IL-4 is the dominant pro-ﬁbrotic mediator in
this disease.
Chiaramonte et al. (2001) further investigated the role of IL-13
on different genetic backgrounds of mice infected with S. mansoni.
They found that C3H/HeN, BALB/c, and C57BL/6 mice develop
high, intermediate, and low levels of ﬁbrosis, respectively. The
ﬁbrotic mechanism of S. mansoni infection tightly correlates with
high IL-13 and low IFN-γ/IL-10. Administration of sIL-13Rα2-Fc
markedly improves liver ﬁbrosis in all strains. More interestingly,
sIL-13Rα2-Fc is highly efﬁcient even when S. mansoni mediated
ﬁbrosis and Th2 cytokine response have been developed (Chiara-
monte et al., 2001).As a decoy receptor, IL-13Rα2 is upregulated by
P-selectin in S. mansoni infection (Wynn et al., 2004a). IL-13Rα2-
deﬁcient mice showed a marked exacerbation in S. mansoni asso-
ciated liver ﬁbrosis due to increased IL-13 activity (Chiaramonte
et al., 2003; Mentink-Kane et al., 2004).
The pro-ﬁbrotic effects of IL-13 are dependent of TGF-β in lung
ﬁbrosis (Lee et al., 2001; Fichtner-Feigl et al., 2006). However, IL-
13 mediated liver ﬁbrosis in schistosomiasis is TGF-β and MMP-9
independent (Kaviratne et al., 2004). S. mansoni infected IL-13 KO
mice almost completely abrogates liver ﬁbrosis in spite of undi-
minished TGF-β production. Further, interfering with TGF-β and
its signaling by neutralizing anti-TGF-β antibody, soluble TGF-
βR-Fc and establishing Smad3 KO and TGF-βRII-Fc transgenic
mice does not modulate development of liver ﬁbrosis and pro-
duction of IL-13 in S. mansoni infected mice. Like TGF-β,MMP-9
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knockout shows no reduction of liver ﬁbrosis in S. mansoni mouse
model either (Kaviratne et al., 2004). These results suggest direct
pro-ﬁbrotic mechanisms of IL-13 in schistosoma infected mice.
Consistent with the ﬁndings from animal models, the tight
link between IL-13 and liver ﬁbrosis was demonstrated in patients
with Schistosomiasis.One study demonstrated signiﬁcantly higher
levels of PBMC IL-13, IL-5, and IL-10 in S. mansoni infected
patients with degree III hepatic ﬁbrosis than in those with degree
I and II hepatic ﬁbrosis (de Jesus et al., 2004). Another study
performed in 91 patients with S. mansoni infection conﬁrmed
a positive correlation between levels of IL-13 and liver ﬁbro-
sis (Alves Oliveira et al., 2006). Interestingly, this study showed
that high levels of TGF-β negatively associated with liver ﬁbro-
sis in S. mansoni infected patients (Alves Oliveira et al., 2006).
A similar result demonstrated that TGF-β downstream signaling
protein, phospho-Smad2, negatively correlates with ﬁbrotic stages
in liver tissues from patients with S. japonicum infection (Weng
et al., 2009). Moreover, a study on 611 patients with S. japonicum
infection in the Philippines further conﬁrmed the association of
Th2 cytokines, including IL-4, IL-5, and IL-13, with liver ﬁbrosis
(Coutinho et al., 2007).
HCV
Although Th1 to Th2 shift has been thought as a critical determi-
nation in chronic hepatitis C, this disease is not a typical Th2
dominated chronic disease. A clinical study failed to ﬁnd sig-
niﬁcantly different levels of IL-4 and IL-13 in peripheral serum
CD4+, CD8+, “naïve”-CD45RA 1, and “memory”-CD45RO 1 T-
cell subsets from 28 patients with chronic HCV infection versus
26 matched controls (Bergamini et al., 2001). However, patients
with chronic HCV infection show Th2 biased characteristics in
Natural killer T (NKT) cells. Invariant NKT (iNKT) cells secrete
both Th1 and Th2 cytokines in chronic HCV infection. Although
the frequency of serum NKT cells in patients with chronic HCV
infection does not differ from those in healthy controls, activated
NKT cells produce higher levels of IL-13 but comparable levels
of IFN-γ with those from healthy subjects (Kanto and Hayashi,
2007). Another study focusing on human iNKT cells reported that
levels of IL-13 and IL-4 in iNKT cells are markedly increased in
either peripheral or intrahepatic tissues in patients with chronic
HBV or HCV infection compared to healthy controls (de Lalla
et al., 2004). Further, levels of IL-13 and IL-4 in patients with cir-
rhosis were signiﬁcantly higher than in those without cirrhosis (de
Lalla et al., 2004). When Durante-Mangoni and colleagues inves-
tigated hepatic CD1d expression in HCV infection, they found
that intrahepatic lymphocytes recognizing CD1d produce high
levels of IFN-γ and some IL-13, but little or no detectable IL-4.
However, cirrhotic liver CD1d reactive T cells could also pro-
duce IL-4 (Durante-Mangoni et al., 2004). Another study reported
no difference in numbers of iNKT cells in pheripheral serum of
patients with chronic HCV infection, but iNKT cells from HCV
patients demonstrate signiﬁcantly enhanced capability to secret
IL-13 compared to those fromhealthy controls (Inoue et al., 2006).
Furthermore, a recent study revealed signiﬁcantly enhanced serum
levels of IL-13 in HCV patients compared to healthy controls
(Weng et al., 2009). Markedly elevated protein expression of IL-13
is detected in patients with HCV associated cirrhosis. In addition,
IL-13 immunohistochemical score correlated with liver ﬁbrotic
stages in these patients (Weng et al., 2009).
HBV
Compared to HCV and NASH/ASH, IL-13 levels in liver tissues
with chronic HBV infection are much lower (Weng et al., 2009).
However, there is still evidence that IL-13 is functionally related to
HBV associated liver ﬁbrosis. A recent study with HBV transgenic
mice reported that either IL-13 or IL-4 derived from NKT cells is
critical for HSC activation (Jin et al., 2011). In this study, Jin and
colleagues investigated liver ﬁbrosis in an HBV transgenic mouse
model. They found that NKT cells are critical in mediating HBV
associated liver ﬁbrogenesis. Enhanced IL-13 and IL-4 expression
were detected in NKT cells in HBV transgenic animals compared
to wild-type mice. Neutralizing monoclonal antibodies against IL-
13 and IL-4 markedly inhibited the expression of α-SMA in HSC
isolating from HBV transgenic mice, suggesting that both IL-13
and IL-4 participate in HSC activation.
NASH AND ASH
IL-13 serum levels are increased in patients with NASH com-
pared to healthy controls (Shimamura et al., 2008). In addition,
upregulated expression of IL-13 in liver tissues from patients with
NASH and ASH was also reported (Weng et al., 2009). More-
over, Shimamura et al. (2008) detected signiﬁcantly increased
IL-13Rα2 expression in activated HSC in biopsied liver tissues
from patients with NASH, but not in healthy controls and patients
with NAFLD, suggesting that instead of function as a decoy recep-
tor, IL-13Rα2 may be required for IL-13 mediated liver ﬁbrosis in
NASH (Shimamura et al., 2008).
IL-13 IN EXTRAHEPATIC FIBROSIS
Besides Schistosomiasis, Th2 type cytokines are dominant in a
series of ﬁbrotic diseases, including interstitial lung disease, sys-
temic sclerosis, rheumatoid arthritis (RA), and Ulcerative colitis
(UC; Wynn, 2003, 2004, 2008).
In idiopathic interstitial pneumonia (IIP), IL-13 expression in
tissue and in bronchoalveolar lavage (BAL) ﬂuid is elevated in
the most common subgroup, idiopathic pulmonary ﬁbrosis (IPF).
IPF is considered a Th2 type disease with inﬂammatory inﬁltrates
prevalent. IL-13 levels were higher in IPF than in the non-speciﬁc
interstitial pneumonia (NSIP), the secondmost common IIPwith-
out inﬂammatory inﬁltrates, but with less ﬁbrosis and better
prognosis (Park et al., 2009). In progressed stages of sarcoidosis,
IL-13 expression is highly elevated in BAL and in peripheral blood
mononuclear cells, compared to lower disease grades and healthy
controls (Hauber et al., 2003), suggesting the elevated expressionof
IL-13 might be a potential therapeutic avenue in this disease. The
connection of IL-13 to lung ﬁbrosis was further strengthened in
animal models. In a mouse model of chronic asthma, IL-13 proved
paramount in airway remodeling, eosinophile accumulation and
ﬁbrosis (Kumar et al., 2002). Further, inhibition of IL-13 signal-
ing via blocking antibodies underlined the importance of IL-13 in
interstitial lung disease, either in animals which were challenged
with Aspergillus fumigatus Conidiae (Blease et al., 2001), or ani-
mals with bleomycin-induced lung ﬁbrosis (Belperio et al., 2002).
In transgenic mice, overexpressing IL-13 in the lungs resulted in
ﬁbrosis (Zhu et al., 1999).
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Further studies showed that IL-13 stimulates airway remod-
eling via induction of speciﬁc MMP’s (Lanone et al., 2002), and
IL-13 is capable of acting directly on airway ﬁbroblasts and sup-
porting their proliferation (Belperio et al., 2002) via induction of
PDGF-alpha (Ingram et al., 2004).
Elevated IL-13 levels have also been reported in systemic scle-
rosis, in RA, and other rheumatic diseases (Spadaro et al., 2002).
The ﬁrst study connecting IL-13 to systemic sclerosis (SSc) was
published in 1997. The authors showed signiﬁcantly elevated IL-
13 levels in the sera of patients with limited cutaneous SSc (lSSc)
and diffuse cutaneous SSc (dSSc) compared to healthy individuals
(Hasegawa et al., 1997). Further, IL-13 levels were found to corre-
late to more aggressive stages of disease (Riccieri et al., 2003). In an
animal model of systemic sclerosis, in which Bleomycin is admin-
istered subcutaneously, similar observations have been achieved
(Matsushita et al., 2004). Consequently, Wynn et al. proved that
IL-13 is responsible for the ﬁbrosis in bleomycin-induced SSc,
and its expression is regulated by the transcription factor T-bet
(Aliprantis et al., 2007).
Rheumatoid arthritis, a disease in which joint inﬂammation
and ﬁbrosis occurs, has long been regarded as a Th1 cell induced
disease and lack of Th2 responses (Toh and Miossec, 2007). Recent
studies demonstrate that Th17 cells play important roles in RA
(Toh and Miossec, 2007). However, besides Th1 and Th17 cells
secreted cytokines, increased IL-13 levels in patients’ sera and syn-
ovial ﬂuids were also detected (Isomaki et al., 1996; Spadaro et al.,
2002). Further,Treatmentwith anti-TNF alpha antibody decreases
IL-13 levels (Spadaro et al., 2002; Tokayer et al., 2002). Another
study also showed elevated IL-13 levels in Still’s disease, an adult
form of juvenile RA (Saiki et al., 2004). However, animal models
which connect Il-13 to extensive scarring in RA are still missing
to date.
Ulcerative colitis is also considered a TH2 type disease, with
recurring episodes of colonic inﬂammation, and in the terminal
stadium widespread ﬁbrosis occurs. It is hypothesized that IL-
13 derived from mononuclear cells, is involved in the pathogenic
changes (Heller et al., 2005). However, in an animal model of
colitis, IL-13 proved to be beneﬁcial in preventing inﬂammatory
changes (Wilson et al., 2011), whereas another study points out its
proinﬂammatory role in UC (Kawashima et al., 2011).
IL-13 RECEPTORS AND IL-13 SIGNALING IN FIBROSIS
IL-13 signals to cells by binding to a complex receptor system
comprised of IL-4Rα and two IL-13 binding proteins, IL-13Rα1
and IL-13Rα2 (Zhang et al., 1997). IL-13 Rα1 is expressed in
healthy tissue and binds IL-13 with low afﬁnity by itself, but when
paired with IL-4α, it binds IL-13 with high afﬁnity and forms a
functional IL-13 receptor that signals and results in activation of
JAK/Stat6 pathway (Hershey, 2003; Figure 1). IL-13Rα2, on the
other hand, is only marginally expressed in normal tissues, but
over-expressed in several abnormal conditions, including in can-
cer cells and during ﬁbrosis (Jakubzick et al., 2002, 2004; Joshi
et al., 2006). In contrast to its interaction with the IL-13Rα1, IL-
13 shows higher afﬁnity binding to IL-13Rα2 which has a short
cytoplasmic tail and thus is generally considered a decoy recep-
tor in murine system as described above (Chiaramonte et al.,
2003; Mentink-Kane et al., 2004; Wynn et al., 2004a). However,
Fichtner-Feigl et al. recently reported that IL-13 signals through
IL-13Rα2 to induce production of TGF-β1 in murine macrophage
cell line. Silencing IL-13Rα2 markedly reduces TGF-β1 and ame-
liorates bleomycin-induced mouse lung ﬁbrosis (Fichtner-Feigl
et al., 2006). Furthermore, IL-13 signals through IL-13Rα2 in
HSC leading to TGF-β1 production and liver ﬁbrosis in vitro
and in a NASH model (Shimamura et al., 2008). These ﬁndings
FIGURE 1 | (A) Canonical and non-canonical IL-13 signaling in cells. IL-13 uses
JAK/STAT6 pathway to transduce its canonical signaling in cells. In addition,
IL-13 activates non-canonical STAT3, Erk1/2, etc., pathways in some settings.
(B) Non-canonical signaling pathways of IL-13 play a critical role in liver
ﬁbrosis. IL-13 interacts with TGF-β signaling pathway to induce CTGF
expression in HSCs via Erk1/2 pathway (Liu et al., 2011).
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nevertheless provideusnew insights for understanding IL-13 func-
tion and signaling in different ﬁbrotic diseases. More advanced
acknowledge with IL-13Rα2 is thus eagerly awaited.
Given that both TGF-β1 and IL-13 are critical for organ ﬁbrosis,
synergic signaling crosstalk during ﬁbrogenesis between these two
major pro-ﬁbrotic cytokines is always a hot topic. IL-13 cooperates
with TGF-β1 to induce ﬁbrosis in some settings (Lee et al., 2001;
Lanone et al., 2002; Fichtner-Feigl et al., 2006). For example, IL-13
is known as a potent inducer of matrix metalloproteinases-9 and
cathepsin-based proteolytic pathways which stimulate cleavage of
latency-associated peptide thus activate TGF-β (Lee et al., 2001;
Lanone et al., 2002). However, the mechanism of IL-13 induced
ﬁbrogenesis is far more complicated than expected. In the context
of schistosoma infected mice, IL-13 induced liver ﬁbrosis is inde-
pendent of TGF-β (Kaviratne et al., 2004). A more recent work
studying CTGF induction in primary HSC further supported a
TGF-β independent mechanism involved in IL-13 induced liver
ﬁbrogenesis (Liu et al., 2011). IL-13 was found to induce CTGF
in a TGF-β independent manner in quiescent HSC, while this
process still requires activation of Smad proteins and participa-
tion of TGF-β type I receptors. Erk–MAPK signaling pathway was
found at least partially to mediate the TGF-β independent Smads
activation involved in IL-13 stimulated CTGF production (Liu
et al., 2011; Figure 1). These ﬁndings suggested that IL-13 medi-
ated ﬁbrosis may be not strictly dependent on the downstream
TGF-β actions. Besides through regulating the production and
activation of TGF-β, IL-13 can also utilize other mechanisms to
drive ﬁbrogenesis.
Another controversial issue involved in IL-13 mediated ﬁbro-
genesis is the participation of Stat6. Signaling through IL-4Rα/IL-
13Rα1 supports Stat6 activation for both IL-4 and IL-13, which is
consistent with the fact that IL-13 shares many functional prop-
erties with IL-4. Stat6 activation upon receptor engagement is
suggested due to the recruitment of Stat6 to the IL-4Rα chain
(Kelly-Welch et al., 2003). A number of studies have demonstrated
that the IL-13, IL-4Rα, and Stat6 pathway is critical for develop-
ment of ﬁbrosis (Fallon et al., 2001; Lee et al., 2001; Chiaramonte
et al., 2003). On the other hand, several studies argued that IL-13-
regulated response, including lung and liver ﬁbrosis, could develop
in the absence of Stat6 (Blease et al., 2002; Fritz et al., 2011; Liu
et al., 2011). A study based on liver tissue from patients with differ-
ent chronic liver diseases revealed that only 5 of 120 IL-13 positive
liver tissue specimens exhibited positive p-Stat6 staining (Weng
et al., 2009), indicating that a Stat6 independent mechanism is
implicated in IL-13 associated liver ﬁbrosis.
PERSPECTIVE
It has been conﬁrmed that IL-13 is a critical pro-ﬁbrotic factor
in liver ﬁbrosis associated with Schistosoma infection. In cul-
tured HSC, IL-13 directly up-regulates expression of collagens and
other pro-ﬁbrotic genes. Recently, the potential role of IL-13 in
non-Schistosoma induced liver ﬁbrogenesis has been uncovered.
The IL-13 receptors, IL-13Rα1 and IL-13Rα2, play differently in
IL-13 signaling pathway. IL-13Rα2 serves as a decoy receptor in
Schistosomiasis, but transmits signaling to activate TGF-β1 pro-
moter in NASH. What is the function of IL-13Rα2 in other IL-13
related chronic liver diseases? Is it possible to use sIL-13Rα2-Fc as
a successful drug to treat liver ﬁbrosis in Schistosomiasis patients?
What kind of role is Stat6 playing in different diseases settings?
These are some eager questions waiting to be explored in the near
future.
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